Anthem Biosciences Share Price
934.30-16.40 (-1.73%)
+13.43% past 1 Year
Anthem Biosciences is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity
Corporate filings & documents
Announcements
Transcript of Earnings Conference Call held on July 22 2026.
1 month agoTranscript of Earnings Conference Call held on July 22 2026.
1 month agoAnthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22 2026
1 month agoAnthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22 2026
1 month agoAnthem Biosciences Limited has informed the Exchange regarding the Proceedings of the 20th Annual General Meeting held on Wednesday July 22 2026
1 month agoAudio recording of Earnings Call for the quarter ended June 30 2026.
1 month agoAudio recording of Earnings Call for the quarter ended June 30 2026.
1 month agoNewspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30 2026
1 month agoNewspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30 2026
1 month agoRevised Press Release on Unaudited Financial Results for the quarter ended June 30 2026
1 month agoRevised Press Release on Unaudited Financial Results for the quarter ended June 30 2026
1 month agoRevised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30 2026
1 month agoRevised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30 2026
1 month agoPress Release on Consolidated Financial Results for the quarter ended June 30 2026
1 month agoPress Release on Consolidated Financial Results for the quarter ended June 30 2026
1 month agoInvestor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30 2026`
1 month agoInvestor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30 2026`
1 month agoFinancials Results for the quarter ended June 30 2026
1 month agoFinancials Results for the quarter ended June 30 2026
1 month agoOutcome of the Board Meeting held on Tuesday July 21 2026
1 month agoOutcome of the Board Meeting held on Tuesday July 21 2026
1 month agoIntimation of Schedule of Earnings Conference Call to discuss on Unaudited Standalone and Consolidated Financial Results for quarter ended June 30 2026
1 month agoIntimation of Schedule of Earnings Conference Call to discuss on Unaudited Standalone and Consolidated Financial Results for quarter ended June 30 2026
1 month agoAnthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2026.
1 month agoAnthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2026.
1 month agoCertificate under Regulation under 74(5) of SEBI (DP) Regulations 2018
1 month agoCertificate under Regulation under 74(5) of SEBI (DP) Regulations 2018
1 month agoLetter to Shareholders providing the weblink and navigation path for accessing the Annual Report for the FY 2025-26 pursuant to Regulation 36(1)(b) of LODR.
1 month agoLetter to Shareholders providing the weblink and navigation path for accessing the Annual Report for the FY 2025-26 pursuant to Regulation 36(1)(b) of LODR.
1 month agoIntimation of Revision in Credit Rating
2 months agoIntimation of Revision in Credit Rating
2 months agoNewspaper advertisement regarding the completion of dispatch of notice of the 20th Annual General Meeting of the Company
2 months agoNewspaper advertisement regarding the completion of dispatch of notice of the 20th Annual General Meeting of the Company
2 months agoRevised Annual Report for the FY 2025-26
2 months agoBusiness Responsibility and Sustainability Report (BRSR) for the FY 2025-2026
2 months agoBusiness Responsibility and Sustainability Report (BRSR) for the FY 2025-2026
2 months agoAnnual Report for the FY 2025-26
2 months agoAnnual Report for the FY 2025-26
2 months agoNotice of the 20th Annual General Meeting
2 months agoNotice of the 20th Annual General Meeting
2 months agoNewspaper Advertisement regarding pre-dispatch intimation of Notice of 20th Annual General Meeting of the Company
2 months agoNewspaper Advertisement regarding pre-dispatch intimation of Notice of 20th Annual General Meeting of the Company
2 months agoClosure of Trading Window for the quarter ended June 30 2026
2 months agoClosure of Trading Window for the quarter ended June 30 2026
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aruna Ganesh
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aruna Ganesh
2 months agoSchedule of Institutional Call to be held on June 10 2026
3 months agoSchedule of Institutional Call to be held on June 10 2026
3 months agoInvestors/Analyst Call Intimation to be schedule from June 02 2026 till June 05 2026.
3 months agoInvestors/Analyst Call Intimation to be schedule from June 02 2026 till June 05 2026.
3 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
Jul 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-06-25
Dividend
2.0
Company details
Registered office
No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area Phase I, Bommasandra Bengaluru Karnataka PIN: 560099 Tel No: 080-66724000 Fax No: 080-40444020 Email: [email protected] Internet: www.anthembio.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Ajay Bhardwaj, Chairman & Managing Director, Chief Executive Officer
Ajay Bhardwaj, Chairman & Managing Director, Chief Executive Officer
Ganesh Sambasivam, Whole Time Director
K Ravindra Chandrappa, Whole Time Director
Satish Chander Subbanna, Nominee Director
Subramanian Madhavan, Non Executive Independent Director
Ravikant Uppal, Non Executive Independent Director
Ramesh Ramadurai, Non Executive Independent Director
Shubha Kulkarni, Non Executive Independent Women Director
Divya Prasad, Company Secretary & Compliance Officer
Details
BSE 544449
NSE ANTHEM
ISIN INE0CZ201020